FPRX Five Prime Therapeutics Inc.

-0.06  -0%
Previous Close 12.99
Open 13.05
Price To Book 1.73
Market Cap 458848837
Shares 35,487,149
Volume 430,008
Short Ratio
Av. Daily Volume 293,632

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 portion of Phase 1/3 trial has been initiated - September 10, 2018. Phase 1 data presented at ASCO GI January 17, 2019 noted 19% ORR.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 1b ongoing.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Solid tumors
Phase 2 complete. Phase 3 development will not be pursued.
Cabiralizumab (FPA008)
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data at ESMO showed ORR 48%.
Mesothelioma cancer
Phase 1b commencement of dosing announced February 21, 2019. Initial data due at ASCO June 2019.
Solid tumors
Phase 2 trial initiated January 2018.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Pancreatic cancer
Phase 1 dosing announced November 14, 2018. Data due 2019.
Solid tumors